Skip to main content

Table 2 Proportion of patients in ultrasound remission, according to different ultrasound remission definitions as well as different clinical remission criteria

From: Using a DAS28-CRP-steered treat-to-target strategy does not eliminate subclinical inflammation as assessed by ultrasonography in rheumatoid arthritis patients in longstanding clinical remission

Patients in DAS28CRP-remission
  All patients (n = 87) csDMARD group (n = 45) bDMARD group (n = 42) Difference between treatment groups (p value)
 Ultrasound strict remission 6 (7%) 0 (0%) 6 (14%) 0.01
 Ultrasound semi-strict remission 32 (37%) 15 (33%) 17 (40%) 0.50
 Ultrasound Doppler remission 49 (56%) 26 (58%) 23 (55%) 0.78
Patients in ACR-EULAR Boolean-remission*
  All patients (n = 67) csDMARD group (n = 34) bDMARD group (n = 33) Difference between treatment groups (p value)
 Ultrasound strict remission 6 (9%) 0 (0%) 6 (18%) 0.01
 Ultrasound semi-strict remission 25 (37%) 12 (35%) 13 (39%) 0.73
 Ultrasound Doppler remission 38 (57%) 21 (62%) 17 (49%) 0.40
Patients in SDAI-remission
  All patients (n = 65) csDMARD patients (n = 34) bDMARD patients (n = 31) Difference between treatment groups (p value)
 Ultrasound strict remission 6 (9%) 0 (0%) 6 (19%) 0.007
 Ultrasound semi-strict remission 26 (40%) 13 (38%) 13 (50%) 0.76
 Ultrasound Doppler remission 38 (59%) 22 (58%) 16 (51%) 0.29
  1. Values are given as number of patients and percentage. Comparison between groups by Pearson chi-square with p < 0.05 considered significant
  2. Ultrasound strict remission no joints with GS score > 0 and Doppler score > 0, ultrasound semi-strict remission no joints with GS score > 1 and Doppler score > 0, ultrasound Doppler remission no joints with Doppler score > 0. csDMARD conventional synthetic disease-modifying anti-rheumatic drug, bDMARD biological disease-modifying anti-rheumatic drug, GS grey scale
  3. *Patients in ACR-EULAR Boolean-remission are identical to patients in CDAI-remission